Xinlitai Class 1 new drug SAL007 was approved clinically for its first Sino-US dual-report innovative biological drug.

Recombinant human neuromodulation protein 1-anti-HER3 antibody fusion protein injection (developed code-named SAL007) is an NRG-1 (neuromodulation protein-1) fusion antibody drug developed by Salubris, a wholly owned sun company of Xinlitai.
the product, the first innovative biologic drug to be reported in both China and the U.S., was approved by the U.S. FDA in February 2020 and is currently conducting human clinical trials in the U.S.
NRG-1 is a group of structural proteins containing skin-like growth factors that regulate cell growth and differentiation by activating tyrosine kinase proteins (HER3, HER4), including playing an important role in the normal development and function of the nervous system and heart.
unique molecular design of THESAL007 solves the limitations of recombinant NRG-1 protein therapy, blocks HER3 subjectivity without affecting HER4 activation, and greatly improves the drug-forming and safety of the product.
clinical results show that the product has a long half-life, good safety characteristics.
In the model of spontaneous chronic heart failure in non-human primates, SAL007 can reverse myocardial lesions, significantly improve the function of heart contraction, and the therapeutic effect is outstanding.
.